



Glaxo Group Limited
980 Great West Road
Brentford
Middlesex
TW8 9GS

T +44 (0)20 8047 5000

10th May 2023

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Sub: Disclosure under regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the F.Y. ended March 31, 2023.

In compliance with the provisions of regulation 31(4) of the SEBI (Substantial Acquisition of & Takeovers) Regulations, 2011 ('SAST Regulations'). We, Glaxo Group Limited, UK, for ourself and on behalf of the promoter group of the GlaxoSmithKline Pharmaceuticals Limited ('the Company') hereby confirm and declare that we, the Promoters along with PAC (Persons Acting in Concert), have not made any encumbrance, directly or indirectly, during the financial year ended March 31, 2023 on the shares held by us in the Company. We further confirm that as on March 31, 2023. There are no shares of the company that are encumbered or pledged by us.

For **Glaxo Group Limited, UK**

Marcus Dowding, Authorised Signatory, Corporate Director

Signature of the Authorised Signatory

(For on behalf of Promoters)

- Glaxo Group Limited, UK
- GlaxoSmithKline Pte Ltd
- Burroughs Wellcome International Limited
- ESKAYLAB LIMITED

Place: Brentford, UK

Date: 10th May 2023